Recent Updates
Recently added Catalysts

1: Liothyronine

Phase 1

Healthy | Small molecule | Other |Viatris Inc.|Last Updated: Sep 16, 2009

Target and mechanism

ModalitySmall molecule

Also known as 1: Liothyronine Sodium Tablets

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLED
Total Trials1
Total Enrollment31

FDA Designations

No designations recorded

Clinical trial landscape

1: Liothyronine · 1 trial · 1 indication

Phase 1 1
NCT00978055Fasting Study of Liothyronine Sodium Tablets (50 Mcg) to Cytomel® Tablets (50 Mcg)Healthy
COMPLETED31 Analytics
PHASE1COMPLETED
Fasting Study of Liothyronine Sodium Tablets (50 Mcg) to Cytomel® Tablets (50 Mcg)
HealthyUnlock trial analytics

Study Endpoints

Primary Endpoints

Bioequivalence
within 30 days
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER

Treatment Arms

ArmTypeDescription
1EXPERIMENTALLiothyronine Sodium Tablets, 50 mcg
2ACTIVE_COMPARATORCytomel® Tablets, 50 mcg

Interventions

NameTypeDescription
1: Liothyronine Sodium TabletsDRUGLiothyronine Sodium Tablets, 50 mcg 2 x 50 mcg, single-dose, fasting
2: Cytomel® TabletsDRUGCytomel® Tablets, 50 mcg 2 x 50 mcg, single-dose, fasting
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * healthy males and/or non-pregnant, non-lactating females, 18 years and older * able to swallow medication Exclusion Criteria: * institutionalized subjects * history of any significant disease * use of any prescription or OTC medications within 14 days prior to start of study...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about 1: Liothyronine

What is liothyronine?

Liothyronine is a small molecule drug developed by Viatris Inc. (ticker VTRS) and is also known as Liothyronine Sodium Tablets. It has been studied in healthy adult volunteers in the United States. The program includes one completed Phase 1 trial with 31 participants.

What is liothyronine used for?

Liothyronine has been evaluated in healthy volunteers rather than in a patient population. The single completed Phase 1 study enrolled healthy adults aged 18 years and older of all sexes in the United States. No disease indication is listed for this program.

Who makes liothyronine?

Liothyronine is developed by Viatris Inc., which trades under the ticker VTRS. The product referenced in the clinical program is Liothyronine Sodium Tablets. Viatris sponsored the Phase 1 study of the drug conducted in the United States.

What phase is liothyronine in?

Liothyronine is in Phase 1 development. The program has one completed Phase 1 trial and no active trials. It is an investigational program in clinical development, and the available information does not indicate that it is approved by the FDA.

What clinical trials is liothyronine in?

Liothyronine has been studied in one completed Phase 1 trial, NCT00978055, titled Fasting Study of Liothyronine Sodium Tablets (50 Mcg) to Cytomel Tablets (50 Mcg). The trial enrolled 31 healthy adult volunteers in the United States, was randomized, and used an active control.

Is liothyronine the same as Liothyronine Sodium Tablets?

Yes, Liothyronine Sodium Tablets is another name for liothyronine. The Phase 1 study NCT00978055 compared Liothyronine Sodium Tablets at 50 mcg with Cytomel tablets at 50 mcg in healthy volunteers. Both names refer to the same drug developed by Viatris Inc.